Advertisement

Nierentransplantation

Chapter
  • 986 Downloads

Auszug

Die Nierentransplantation ist die effektivste Behandlungsmethode der chronischen terminalen Niereninsuffizienz. Seit den 1960er Jahren entwickelte sie sich zu einer Standardtherapie. Wichtige Voraussetzungen waren die Entdeckung des HLA-Systems, die Entwicklung der Immunsuppressiva sowie die technische Perfektionierung des Organerhaltes außerhalb eines lebenden Körpers. Die 5-Jahres-Überlebensrate für Allotransplantate beträgt etwa 65%, diejenige von Lebendspenden 79%.

Literatur

  1. Beimler J, Zeier M (2006) Management von Patienten auf der Transplantationsliste unter besonderer Beachtung immunologischer Aspekte, Mitteilungen de deutschen Arbeitsgemeinschaft für Klinische Nephrologie, XXXV; 83–90Google Scholar
  2. Bloom RD, Olivares M, Rehman L, Raja RM, Yang S, Badosa F (1997) Long-term pancreas allograft outcome in simultaneous pancreas-kidney transplantation: a comparison of enteric and bladder drainage. Transplantation 64:1689–1695PubMedCrossRefGoogle Scholar
  3. Broeders N, Wissing KM, Crusiaux A, Kinnaert P, Vereerstraeten P, Abramowicz D (1998) Mycophenolate mofetil, together with Ciclosporin A, prevents anti-OKT 3 antibody response in kidney transplant recipients. J Am Soc Nephrol 9:1521–1525PubMedGoogle Scholar
  4. Carpenter CB (1990) Immunosuppression in organ transplantation. N Engl J Med 322:1224–1226PubMedCrossRefGoogle Scholar
  5. Colvin RB, Cohen AH, Saiontz C, Bonsib S, Buick M, Burke B, Carter S, Cavallo T, Haas M, Lindblad A, Manivel JC, Nast CC, Salomon D, Weaver C, Weiss M (1997) Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 8:1930–1941PubMedGoogle Scholar
  6. Feucht HE, Opelz G (1996) The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 50:1464–1475PubMedGoogle Scholar
  7. First MR, Alloway R, Schroeder TJ (1998) Development of Sang-35: a Ciclosporine formulation bioequivalent to Neoral. Clin Transplant 12:518–524PubMedGoogle Scholar
  8. Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338:1741–1751PubMedCrossRefGoogle Scholar
  9. Frei U, Schindler R (2000) Nierentransplantation. In: Koch KM (ED) Klinische Nephrologie. Urban & Fischer, München Jena, S:779–814Google Scholar
  10. Hammoud J, Haem J, Laurent B et al (1996) Glomerular diseaseduring HCV infection in renal transplantation. Nephrol Dial Transplant 11:54–58PubMedGoogle Scholar
  11. Jassal SV, Roscoe JM, Zaltzman JS, Mazzulli T, Krajden M, Gadawski M, Cattran DC, Cardella CJ, Albert SE, Cole EH (1998) Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 9:1697–1708PubMedGoogle Scholar
  12. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT (1998) Immunosuppressive effects and safety of a sirolimus/Ciclosporine combination regimen for renal transplantation. Transplantation 66:1040–1046PubMedCrossRefGoogle Scholar
  13. Matas AJ, Gillingham KJ, Payne WD, Najarian JS (1994) The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57:857–859PubMedCrossRefGoogle Scholar
  14. Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Fischer G, Fae I, Middleton D, Savage D et al. (1993) Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation 55:782–785PubMedGoogle Scholar
  15. Opelz G, Vanrenterghem Y, Kirste G et al. (1997) Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63:964–967PubMedCrossRefGoogle Scholar
  16. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, Delmonico FL (1998) Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 66:1460–1464PubMedCrossRefGoogle Scholar
  17. Patton PR, Brunson ME, Pfaff WW, Howard RJ, Peterson JC, Ramos EL, Karlix JL (1994) A preliminary report of diltiazem and ketoconazole. Their Ciclosporine—sparing effect and impact on transplant outcome. Transplantation 57:889–892PubMedCrossRefGoogle Scholar
  18. Paya CV, Fung JJ, Nalesnik MA et al. (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation Nov 27;68(10):1517–1525PubMedCrossRefGoogle Scholar
  19. Sanfilippo F (1998) Transplantation tolerance — the search continues. N Engl J Med 339:1700–1702PubMedCrossRefGoogle Scholar
  20. Smit H, Molzahn M, Kirste G, Grupp R, Köhler A für die Deutsche Stiftung Organtransplantation (2000) Organspende und Transplantation in Deutschland 1999. 5ter Bericht. Visuelle Kommunikation, ObertiefenbachGoogle Scholar
  21. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF et al. (1993) International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44:411–422PubMedGoogle Scholar
  22. Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F (1998) Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 13:711–715PubMedCrossRefGoogle Scholar
  23. Vella JP, Sayegh MH (1997) Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J 73:386–390PubMedCrossRefGoogle Scholar
  24. Wuthrich RP, Weinreich T, Ambuhl PM, Schwarzkopf AK, Candinas D, Binswanger U (1999) Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil. Nephrol Dial Transplant 14:394–399PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2007

Personalised recommendations